Head-to-head · Cost-Efficiency Index
NewSelf vs Ro
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NewSelf
Budget shoppers who want a verified all-50 program and one of the lowest disclosed tirzepatide prices in the value tier.
Visit NewSelfRo
People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Visit RoThe verdict
NewSelf takes it, leading the Cost-Efficiency Index 87 to 84. $100 semaglutide and $144 tirzepatide, nationwide and LegitScript-verified — near-identical value to the cheapest verified names, with the tirzepatide price a hair lower than most. Ro still earns a B — People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs NewSelf.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NewSelf | Ro |
|---|---|---|
| Cost-Efficiency Index | 87/100 | 84/100 |
| Semaglutide / mo | $100/mo | Not disclosed |
| Tirzepatide / mo | $144/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,200 | — |
| Tirzepatide / yr (modeled) | $1,728 | — |
| Coverage | All 50 states | Multi-state |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #6 | #19 |
NewSelf
87/100Where the value is
- $100 semaglutide / $144 tirzepatide — one of the cheapest verified combined prices on the board
- Nationwide all-50 coverage with both molecules published up front
- LegitScript-certified pharmacy behind the low price
The tradeoffs
- Compounded only — no brand-name or oral option
- Newer consumer brand with a thin public track record
Ro
84/100Where the value is
- Brand-name access and insurance support
- Oral options widen the formulary
- Polished, well-funded platform
The tradeoffs
- Does not publish compounded pricing up front — a blind spot in any cost model
- Premium positioning
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.